BeiGene, a global oncology company, has established its flagship U.S. facility in Hopewell, New Jersey, aiming to bolster its manufacturing and clinical development capabilities. The investment, totaling $800 million, has resulted in a state-of-the-art facility contributing to BeiGene’s innovative oncology model.
The 42-acre campus houses advanced biologics manufacturing capabilities, enabling the flexible production of BeiGene’s 30 clinical or commercial-stage molecules. This investment anticipates future growth in the company’s pipeline and supports its mission of delivering quality cancer medications to patients worldwide.
The facility will create hundreds of high-tech jobs by 2025, contributing to New Jersey’s prominence as a global biopharmaceutical R&D and manufacturing hub. BeiGene’s investment is a testament to the state’s infrastructure, workforce, and proximity to major markets.
Governor Phil Murphy expressed enthusiasm for BeiGene’s contribution to New Jersey’s biopharmaceutical sector, highlighting the state’s commitment to innovation and high-tech job creation. BeiGene’s presence is anticipated to impact the economy and advance cancer treatment positively.
The Hopewell facility includes approximately 400,000 square feet of commercial-stage biologic manufacturing capacity, which can be expanded to accommodate BeiGene’s growing pipeline. It complements the company’s late-stage research and clinical development capabilities, enhancing its ability to expedite the development of novel cancer therapies.
BeiGene’s expansion in New Jersey aligns with its mission to develop affordable and accessible treatments for cancer patients globally. The company’s continued growth and innovation will contribute to advancing cancer care, offering hope to patients worldwide.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.